Identification of Host Cellular Protein Substrates of SARS-COV-2 Main Protease by Miczi, Márió et al.
 International Journal of 
Molecular Sciences
Article
Identification of Host Cellular Protein Substrates of
SARS-COV-2 Main Protease
Márió Miczi 1,2, Mária Golda 1,2, Balázs Kunkli 1,2 , Tibor Nagy 3 , József Tőzsér 1
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Abstract: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative
agent of coronavirus disease-19 (COVID-19) being associated with severe pneumonia. Like with other
viruses, the interaction of SARS-CoV-2 with host cell proteins is necessary for successful replication,
and cleavage of cellular targets by the viral protease also may contribute to the pathogenesis,
but knowledge about the human proteins that are processed by the main protease (3CLpro)
of SARS-CoV-2 is still limited. We tested the prediction potentials of two different in silico methods
for the identification of SARS-CoV-2 3CLpro cleavage sites in human proteins. Short stretches of
homologous host-pathogen protein sequences (SSHHPS) that are present in SARS-CoV-2 polyprotein
and human proteins were identified using BLAST analysis, and the NetCorona 1.0 webserver was used
to successfully predict cleavage sites, although this method was primarily developed for SARS-CoV.
Human C-terminal-binding protein 1 (CTBP1) was found to be cleaved in vitro by SARS-CoV-2
3CLpro, the existence of the cleavage site was proved experimentally by using a His6-MBP-mEYFP
recombinant substrate containing the predicted target sequence. Our results highlight both potentials
and limitations of the tested algorithms. The identification of candidate host substrates of 3CLpro
may help better develop an understanding of the molecular mechanisms behind the replication and
pathogenesis of SARS-CoV-2.
Keywords: COVID-19; coronavirus; SARS; SARS-CoV-2; main protease; 3CL protease; NetCorona;
SSHHPS; cleavage site identification; cleavage site prediction; host protein cleavage
1. Introduction
A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in
December 2019 as the causative agent of coronavirus disease-19 (COVID-19) that occurred first in Wuhan,
Hubei province, China [1]. According to the data that were reported to the World Health Organization
up to 10 December 2020, the global SARS-CoV-2 pandemic was associated with >68.16 million confirmed
cases of infections and >1.55 million virus-related deaths worldwide (https://covid19.who.int).
In general, viruses rely on the host machinery for the efficient infection and for the completion of
the replication cycle, furthermore, changing expression profiles of host genes and interactions with the
host proteins can also help the virus to evade the immune reaction after the infection, as it was observed
in the case of SARS-CoV and SARS-CoV-2 infection, as well [2–5]. It is known that SARS coronavirus
infection can influence multiple tissues or organs, including the respiratory system [6], coagulation
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system [7,8], gastrointestinal tract [9], or nervous system [10]. Numerous interacting partners of
SARS-CoV-2 proteins have already been identified [3], but the detailed function and proteolytic targets
of SARS-CoV-2 in the host cells are still understudied, however, various symptoms may be connected
in part with the destruction of host proteins.
The genome of SARS-CoV-2 codes for multiple non-structural proteins (nsp) including two cysteine
proteases, a papain-like protease (nsp3, PLpro), and a 3-chymotrypsin-like protease (nsp5, 3CLpro,
or main protease), this last one is responsible for most of the processing of the viral polyprotein.
Both SARS-CoV and SARS-CoV-2 3CL proteases consist of three domains. Domain I and II contain
antiparallel β-barrels, while domain III has a helical arrangement. The active site comprises His41 and
Cys145 catalytic residues [11–13].
SARS-CoV and SARS-CoV-2 3CL proteases share high sequence identity (96%) [14] and differ only
in few residues (Figure 1a), including the Ser46 (SARS-CoV-2 3CLpro numbering) which serine residue
is located in the proximity of the active site of the enzyme (Figure 1b) but is not involved in the formation
of any substrate binding subsite (Figure 1c). The substrate-binding cleft is located between domain I
and II, and the substrate-binding subsites show high conservation [11–13]. Each amino acid side chain
of the substrate (P4-P4’) which fit in a successive subsite of the enzyme (S4-S4’) is named according
to the notation of Schecter and Berger [15]. The S4 site of the protease is a shallow hydrophobic site,
while S3 enables binding of a wide range of residues, including hydrophobic (e.g., Val), polar (e.g., Thr),
or basic (Arg, Lys) residues, because P3 residue is exposed to the solvent. S2 and S1 are deep sites,
S2 shows a preference for hydrophobic P2 residues (Leu, Phe, Val) of autoproteolytic cleavage sites
of the polyprotein, while S1 pocket specifically binds P1-Gln residue. The relatively shallow S1′ site
mainly binds Ser or Ala residues, while the deep and hydrophilic S2′ site can accept a wide variety
of the residues even a large Lys. Similar to P3, the P3′ residue is also exposed to the solvent, thus
specific interactions are not formed with the protease at this site, and the shallow hydrophobic S4′ site
also can bind various residues [11–13]. The high conservation of substrate binding subsites implies
that efficient inhibitors may target a wide range of CoV 3CL proteases [13], and the specificity of
SARS-CoV-2 3CLpro may be highly comparable with that of SARS-CoV.
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Figure 1. Comparison of SARS-CoV and SARS-CoV-2 3CL proteases. (a) Sequence alignment of the
proteases is shown, only those residues are represented for SARS-CoV 3CLpro that are different as
compared to SARS-CoV-2 3CLpro. Active site residues are green and underlined, residues that differ in
the two proteases are red. (b) Schematic structure of SARS-CoV-2 3CLpro based on its X-ray crystal
structure (6LU7.pdb). Catalytic residues (His41 and Cys145) are highlighted by green color, the residues
that are different in SARS-CoV and SARS-CoV-2 3CL proteases are shown by red. Ser46 residue
is also highlighted. Inhibitor bound to the active site is also shown by sticks. (c) Compositions of
substrate binding subsites are shown based on literature data [11–13,16], subsite nomenclature is shown
according to Schechter and Berger [15].
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The autoproteolytic cleavage site sequences of SARS-CoV and SARS-CoV-2 3CL polyproteins have
already been described [17,18], but only a few cleavage sites were identified in host target proteins.
It has been reported that SARS-CoV 3CLpro can cleave cellular V-ATPase G1 in vitro [19], and A549
human lung carcinoma cells overexpressing SARS-CoV 3CLpro showed down-regulated NF-κB
production [20], the decreased NF-κB protein level may possibly be a consequence of the proteolytic
processing of NF-κB by SARS-CoV 3CLpro. Based on the high-confidence interaction of SARS-CoV-2
3CLpro, histone deacetylase 2 (HDAC2) was also identified as a candidate target, and the catalytically
inactive protease was found to interact with tRNA methyltransferase 1 (TRMT1), as well [3]. To date,
only a single in vitro study has been reported in which an LC-MS based N-terminomics approach
was applied to identify host targets of SARS-CoV and CoV-2 3CLpro by incubating the recombinantly
expressed enzymes with cell lysates of lung and epithelial cells. Numerous host targets have been
identified, the obtained cleavage site preferences which were derived from in vitro proteomic analyses
revealed a high preference for P1-Gln, P2-Leu, and P1’-Gly/Ala/Ser residues [21].
The in silico methods are useful tools for the prediction of cleavage site sequences,
such tools were designed for some viral proteases, e.g., for human immunodeficiency virus
proteases (HIVcleave webserver) [22], picornaviral proteases (NetPicoRNA v. 1.0 webserver) [23],
Group IV viral proteases [24,25], and an algorithm has also been developed for SARS-CoV 3CLpro
(NetCorona 1.0 webserver) [26]. The identification of short stretches of homologous host-pathogen
protein sequences (SSHHPS) was also used successfully to determine cleavage sites of Zika virus
and Venezuelan equine encephalitis virus (VEEV) proteases in multiple human target proteins [24].
This method is based on the principle that host proteins may also contain such sequences that are
identical with cleavage site sequences of viral polyproteins, therefore, may be potentially targeted
by the viral protease. The NetCorona webserver was developed based on multiple cleavage site
sequences of coronavirus polyproteins and is applicable for the prediction of potential cleavage sites of
SARS-CoV 3CLpro, thus can be used for the identification of proteolytic targets and for inhibitor design,
as well [26]. This algorithm was applied previously to predict cleavage sites in the nucleocapsid protein
of porcine epidemic diarrhea virus (PEDV) 3CLpro [27], in the equine coronavirus polyprotein [28],
or in human protein targets of SARS-CoV 3CLpro while developing the method [26]. In the case of
SARS-CoV-2 3CLpro, glutathione peroxidase 1, selenoprotein F, and thioredoxin reductase 1 were
proposed to be host substrates by using in silico algorithms [29], but the results were not validated
in vitro. These proteins were not identified in the recently reported proteomic analysis as substrates of
SARS-CoV-2 3CLpro [21], although, in vitro identification of host targets in additional cell types remain
to be performed. Therefore, the application of in silico methods may aid the identification of proteolytic
targets, and results of in silico analyses can be correlated with those of in vitro measurements to assess
the reliability of predictions, which are widely used in the computational drug design.
Accordingly, in this study, we aimed to apply SSHHPS analysis and the NetCorona 1.0 webserver
to predict SARS-CoV-2 3CLpro cleavage sites. BLAST analysis was used to identify SSHHPS in human
proteins, while NetCorona v. 1.0 webserver was applied for the prediction of cleavage probabilities.
Structures of potential targets were also investigated to determine surface accessibilities of the
predicted cleavage sites. Experimental approaches, including the design and use of His6-MBP-mEYFP
recombinant protein substrates (MBP, maltose-binding protein; mEYFP, monomeric enhanced yellow
fluorescent protein) were also applied to prove susceptibility for processing by SARS-CoV-2 3CLpro.
2. Results
2.1. Comparison of SARS-CoV and SARS-CoV-2 Protease Cleavage Sites
First, we compared the autoproteolytic cleavage site sequences of SARS-CoV and SARS-CoV-2
3CLpro and found that the recognition sites closely resemble each other (Figure 2). Similar to
SARS-CoV [21,30], SARS-CoV-2 3CLpro cleavage sites also contain a conserved Gln residue in the P1
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position, and there are hydrophobic (Leu, Phe, or Val) and small aliphatic residues (mainly Ser or Ala)
in P2 and P1’ positions, respectively.
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2.2. Testing NetCorona 1.0 ebserver for Prediction of SARS-CoV-2 3CLpro Cleavage Sites
First, we tested whether NetCorona 1.0 algorithm is suitable for the identification of autoproteolytic
cleavage sites within the SARS-CoV-2 polyprotein. As was expected, no NetCorona score was predicted
for the cleavage sites of PLpro (nsp1, nsp2, and nsp3) because these sites are different from the
consensus pattern of 3CLpro. Cleavage sites of 3CLpro were identified successfully by the webserver
(Table 1), only the nsp5 site resulted in a score being slightly below the threshold, indicating that 87%
sensitivity of the method [26] may be a limiting factor of prediction. The results implied that the
NetCorona 1.0 webserver can be potentially applied to predict cleavage sites of SARS-CoV-2 3CLpro.
Table 1. Prediction of cleavage sites of SARS-CoV-2 polyprotein by NetCorona 1.0 webserver. Sequence
of SARS-CoV-2 polyprotein was used as input [31]. Values lower than the threshold (0.5) are not
predicted as a potential cleavage site. Cleavage positions are shown by asterisks.
SARS-CoV-2 Cleavage Site Protease Sequence NetCorona 1.0 Score
nsp1 PLpro ELNGG*AYTRY no score given
nsp2 PLpro TLK G*APTKV no score given
nsp3 PLpro ALK G*KIVNN no score given
nsp4 3CLpro SAVLQ*SGFRK 0.891
nsp5 3CLpro G TFQ*SAVKR 0.458
nsp6 3CLpro VATVQ*SKMSD 0.783
nsp7 3CLpro RATLQ*AIASE 0.838
nsp8 3CLpro AVKLQ*NNELS 0.860
nsp9 3CLpro TVRLQ*AGNAT 0.904
nsp10 3CLpro EPMLQ*SADAQ 0.865
nsp12 3CLpro HTVLQ*AVGAC 0.905
nsp13 3CLpro VATLQ*AENVT 0.680
nsp14 3CLpro FTRLQ*SLENV 0.964
nsp15 3CLpro YPKLQ*SSQAW 0.899
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2.3. Identification of Host Targets by SSHHPS Analysis and NetCorona Prediction
The NetCorona algorithm was found to be an effective tool for the prediction of those cleavage sites
within the full-length polyprotein sequences which show the consensus pattern (Table 1), no additional
cleavage sites were identified in the polyprotein.
We assumed that other methods that are based on the similarities of sequence motifs may also be
applicable for cleavage site identification. Such a method is the SSHHPS analysis of which prediction
potential has already been proved in the case of Group IV proteases [24,25]. We applied this method
to find candidate targets of SARS-CoV-2 3CLpro, the SSHHPS were identified in human proteins by
BLAST analysis using autoproteolytic cleavage site sequences of SARS-CoV-2 polyprotein as input
(Table 1).
The results of SSHHPS analyses are shown in Table S1 for all cleavage sites of SARS-CoV-2
polyprotein. Numerous human proteins were found to contain such a site that is similar to
the autoproteolytic cleavage sites of the polyprotein, highest similarities were obtained e.g.,
for C-terminal-binding protein 1 and 2 (CTBP1 and CTBP2), dihydropyrimidinase-related protein
2, protein tyrosine kinase 6 (PTK6), acetylcholinesterase (ACHE), protocadherin 19, JNK1/MAPK8-
associated membrane protein, or obscurin proteins (Table S1).
SSHHPS analysis showed a high similarity of a sequence motif of human PTK6 protein
(89VRRLQ*AEGNA98) with that of the viral polyprotein (nsp9, TVRLQ*AGNAT). Accordingly, this site
was identified by NetCorona 1.0 webserver with a relatively high probability, indicating that PTK6
contains a putative cleavage site of 3CLpro (Figure 3).
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Human CTBP1 protein was also predicted to contain a sequence motif (373ELNGAAYRYP382)
which is similar to the nsp1 site of SARS-CoV-2 polyprotein (ELNGG*AYTRY). The relatively high
score obtained for this site by SSHHPS analysis indicated that CTBP1 may also be a proteolytic target.
However, the identified cleavage site is likely to be a cleavage site of PLpro, the putative target sequence
does not resemble the consensus pattern of 3CLpro cleavage sites and contains no glutamine in the
P1 position. Despite this, the sequence of CTBP1 was analyzed by the NetCorona 1.0 webserver,
as well (Figure S1). As it was expected, the single motif (373ELNGAAYRYP382) of CTBP1-identified
by SSHHPS analysis-was not predicted as a putative cleavage site of 3CLpro, but interestingly the
prediction revealed a putative 3CLpro cleavage site in CTBP1 (153GTRVQ*SVEQI162), which was not
identified by SSHHPS analysis based on similarity with nsp4-15 cleavage sites.
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These results implied that the SSHHPS analysis may also be potentially applicable for the
identification of the cleavage sites of PLpro, however, testing prediction potential in the case of PLpro
was out of the scope of this study. NetCorona 1.0 webserver is applicable only for the prediction of
3CLpro sites.
2.4. Selection of Targets for In Vitro Investigation
Out of the possible targets identified by in silico sequence analyses, we selected CTBP1 and PTK6
for further investigation. These proteins were identified as candidate substrates of SARS-CoV-2 3CLpro
using NetCorona 1.0 webserver, as well (Figure 3). Interleukin-1 receptor-associated kinase 1 (IRAK1)
was predicted previously to be potentially cleaved by SARS-CoV 3CLpro [26], thus it was also selected
for testing its proteolysis in vitro. We decided to include IRAK1 in this study in order to prove that
potential targets of SARS-CoV 3CLpro may be accessible for cleavage by SARS-CoV-2 3CLpro, as well.
Furthermore, to our best knowledge, cleavage of IRAK1 by SARS-CoV or SARS-CoV-2 3CLpro has not
been proved experimentally to date. Interestingly, the cleavage site in IRAK1 was not identified by
SSHHPS analysis, however, it was predicted with a high score by the NetCorona algorithm (Figure 3).
This may highlight a limitation of SSHHPS analysis and implies that the number of potential targets
may depend on the settings of the BLAST search.
It has already been described that COVID-19 caused by SARS-CoV-2 infection may lead to
coagulation disorders and increased risk of venous thromboembolism [7]. Therefore, we investigated
whether some human plasma proteins that may be susceptible to proteolysis by SARS-CoV-2 3CLpro.
The sequences of these proteins were analyzed only by the NetCorona algorithm, SSHHPS were
not identified by BLAST analysis in these proteins. Human plasminogen (PLMN) and plasminogen
activator inhibitor 2 (PAI2) were identified as candidate substrates, while fibrinogen, plasminogen
activators, and plasminogen activator inhibitor 1 (PAI1) were predicted to contain no putative 3CLpro
cleavage site (Table S2). A higher score was obtained for PLMN as compared to PAI2, therefore,
we selected PLMN for testing cleavage in vitro (Figure 3).
Identification of some plasma proteins (PLMN, PAI2) as potential targets by the NetCorona
webserver implied that SSHHPS analysis alone may be not sensitive enough for the high throughput
identification of protease substrates, however, these methods are based on different approaches
for cleavage site identification, and the number of identified sites may depend on BLAST settings
(e.g., length of query sequence). Additionally, we assumed that structural contexts of the putative
cleavage sites need to be considered, therefore, accessibilities of target regions were also determined.
A similar in silico approach has already been applied for the identification of potential cleavage sites
in host selenoproteins and enzymes of glutathione synthesis [29], but neither proteomic [21] nor
specifically targeted analyses proved cleavages of these targets in vitro to date. Interestingly, PAI2 was
identified as a substrate of SARS-CoV and hCoV-NL63 3CLpro, as well, while cleavage of PLMN was
not detected by a proteomic analysis [21].
To investigate whether the candidate substrates are sensitive towards proteolysis by SARS-CoV-2
3CLpro in vitro, we selected CTBP1, PTK6, IRAK1, and PLMN recombinant proteins because of
the potential cleavage sites of these proteins were found to be exposed to the surface (Figure 3).
The putative cleavage site in acetylcholinesterase (ACHE) was found to be buried in the structure,
therefore, ACHE was excluded from further analysis. Example of ACHE proved the importance
of structural analysis of candidate substrates: the possible target sequences may be inaccessible for
proteolysis even the high probability of cleavage that was implied by sequence-based prediction
(e.g., by NetCorona v. 1.0).
2.5. In Vitro Cleavage of Recombinant Proteins by SARS-CoV-2 3CLpro
For in vitro cleavage reactions we used untagged SARS-CoV-2 3CLpro. The protease was
expressed in BL21(DE3) cells fused to an N-terminal His6-tag and then purified by Ni-NTA affinity
chromatography. After the enzymatic removal of His6-tag using Factor Xa, the untagged enzyme
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was further purified by ion-exchange chromatography. The purity of the enzyme was assessed by
SDS-PAGE (Figure 4).
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Cleavage reactions ere perfor ed by SARS-CoV-2 3CLpro to investigate the susceptibility of the
selected human proteins for proteolysis (Figure 5). Additionally, a His6-MBP-mEYFP reco binant
protein containing a natural cleavage site of SARS-CoV-2 3CLpro (nsp4, TSAVLQ*SGFRKM) was also
designed and applied as a positive control substrate in the in vitro cleavage reactions. The NetCorona
score obtained for the recombinant substrate was identical to the value calculated for the AVLQ*SGFR
cleavage site of the polyprotein (Table 1). As was expected, the His6-MBP-TSAVLQ*SGFRKM-mEYFP
fusion protein substrate was cleaved very efficiently by the protease. The substrate a d cleavage
products were separated by denaturing SDS-PAGE and then detected in the gel using UV
transillumination, which indicated successful i -gel renaturation of mEYFP (Figure 5a).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 19 
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For negative control, we applied bovine serum albumin (BSA) as a substrate of the untagged
enzyme. Neither SSHHPS analysis nor NetCorona webserver predicted SARS-CoV-2 3CLpro cleavage
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sites in BSA (Table S2), in agreement with this we found that BSA was not processed by the protease
(Figure 5b).
PLMN was also predicted to contain a putative cleavage site, but we observed no processing
(Figure 5c). However, the NetCorona score obtained for the putative cleavage site was above the
threshold (0.5) but was below the highest probability range (0.8–1.0) (Figure 3).
IRAK1 was identified previously as a candidate target of SARS-CoV 3CLpro [27], but its processing
by a coronavirus 3CLpro has not been proved to date, therefore, IRAK1 was also subjected to proteolysis.
We observed almost complete turnover of IRAK1 upon cleavage by SARS-CoV-2 3CLpro (Figure 5d),
proving that IRAK1 is a proteolytic target of SARS-CoV-2 3CLpro. In this study, this protein was not
newly identified as a candidate substrate, thus, was not further investigated in vitro.
CTBP1 protein was found to be processed but we observed lower turnover as compared to
IRAK1 (Figure 5e). The appearance of cleavage products implied processing of CTBP1, we assumed
that this cleavage occurs within the cleavage site identified by the NetCorona v. 1.0 webserver
(153GTRVQ*SVEQI162). In order to prove the existence of cleavage between 157th and 158th residues,
processing of CTBP1 was further investigated, as it is described later.
PTK6 was identified as a potential target both by SSHHPS analysis and NetCorona prediction,
but we did not detect its processing by SARS-CoV-2 3CLpro (Figure 5f). It is important to note that
the recombinant PTK6 was supplied in a buffer containing phenylmethylsulfonyl fluoride (PMSF)
which is known to be able to effectively inhibit numerous serine proteases (including chymotrypsin
and trypsin). Therefore, to exclude the possibility that the processing of PTK6 was impaired by PMSF,
we investigated its effect on SARS-CoV-2 3CLpro activity. We found that PSMF does not inhibit
the processing of His6-MBP-TSAVLQ*SGFRKM-mEYFP recombinant substrate, even at 0.005% (m/v)
final concentration (Figure 6b). This implied that PMSF present in the stock solution cannot prevent
proteolysis and proved that PTK6 is not a proteolytic target of SARS-CoV-2 3CLpro.
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Figure 6. Effect of N-terminal His6 tag and PMSF on SARS-CoV-2 3CLpro activity. (a) In cleavage
reactions we used His6-MBP-TSAVLQ*SGFRKM-mEYFP as a substrate of His6-tagged and untagged
forms of SARS-CoV-2 3CLpro. (b) The effect of PMSF on the cleavage of His6-MBP-TSAVLQ*SGFRKM-
mEYFP was studied, using untagged protease. PMSF was dissolved in ethanol and was applied in
0.005–0.00005% (m/v) concentration range. Uncleaved substrate is shown in figure part (a). Gel images
are representatives of ≥2 parallel experiments.
The effect of the N-terminal His6-tag on the activity of 3CLpro was also tested, and the His6-tagged
enzyme was unable for processing the recombinant substrate (Figure 6a). This in agreement with the
findings of Grum-Tokars et al. who revealed a dramatic decrease of SARS-CoV 3CLpro activity upon
addition of N- or C-terminal affinity tags [32].
In order to investigate the possible causes of why we observed no proteolysis in the case of some
candidate targets, we further analyzed the structures and compared the accessibilities of the putative
cleavage sites (Figure 7). The comparison of solvent-accessible surface areas of PTK6, PLMN, IRAK1,
and CTBP1 structures showed that P5–P1 and P1’–P5’ residues may have relatively lower accessibility in
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PTK6 and PLMN, respectively. We assume that relatively lower solvent accessible surface areas (SASA)
of these sites may prevent efficient binding and cleavage of the substrate. In contrast, the average
values obtained for P5–P5’ residues are more comparable in CTBP1 and IRAK1 proteins and show
relatively higher overall accessibility of the putative cleavage site, however, a threshold was not
determined. We assumed that the relatively lower cleavage efficiency of CTBP1 may be caused in part
by the accessibilities of P2’–P5’ residues of 153GTRVQ*SVEQI162 site which are located in an α-helix,
while the entire target site of IRAK1 is located in a loop region. The relatively higher accessibilities of
cleavage sites are in agreement with the susceptibilities of CTBP1 and IRAK1 for proteolysis in vitro
(Figure 5) and indicate that probabilities of cleavage sites predicted by the NetCorona webserver need
to be interpreted by considering surface accessibilities of putative sites, as well. Our result highlights
that determination of apparent accessibilities of cleavage sites in the protein structures is not sufficient
enough (Figure 2); in agreement with the results of Taylor and Radding [29], we also suggest the
detailed determination of structural characteristics, especially the calculation of numerical SASA values
(Figure 7) for more reliable cleavage site prediction.
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His6-MBP-REGTRVQ*SVEQIRE-mEYFP protein contained that cleavage site sequence which was 
identified CTBP1 by NetCorona algorithm (153GTRVQ*SVEQI162). 
As it was expected, His6-MBP-TSAVLQ*SGFRKM-mEYFP was processed by SARS-CoV-2 
3CLpro (Figure 5a), and we observed proteolysis of His6-MBP-REGTRVQ*SVEQIRE-mEYFP protein 
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Figure 7. Analysis of surface-accessible surface areas. Relative surface-accessible surface area (SASA)
values (%) determined for all atoms in PTK6, PLMN, IRAK1, and CTBP1, and were averaged for every
position in a 5-residue window. Values for P5–P5’ residues are highlighted by red, the average-of-average
and SD values calculated for P5–P5’ sites are shown in brackets. Residue numbering starts in each case
from the first residue of the protein in the coordinate file.
2.6. Identification of Cleavage Position in CTBP1 and in His6-MBP-mEYFP Substrates
We designed and prepared His6-MBP-mEYFP recombinant fusion proteins which were used as
substrates of SARS-CoV-2 3CLpro. A His6-MBP-TSAVLQ*SGFRKM-mEYFP substrate contained the
natural nsp4 cleavage site of SARS-CoV-2 polyprotein, while a His6-MBP-REGTRVQ*SVEQIRE-mEYFP
protein contained that cleavage site sequence which was identified CTBP1 by NetCorona
algorithm (153GTRVQ*SVEQI162).
As it was expected, His6-MBP-TSAVLQ*SGFRKM-mEYFP was processed by SARS-CoV-2 3CLpro
(Figure 5a), and we observed proteolysis of His6-MBP-REGTRVQ*SVEQIRE-mEYFP protein as well.
The substrate turnover was lower as compared to His6-MBP-TSAVLQ*SGFRKM-mEYFP which implies
lower cleavage efficiency for the CTBP1 cleav ge site (Figure 8). This is in contrast with the obtained
cleavage probabilities, as a higher NetCorona score was obtained for the CTBP1 cleavage site (0.946) as
compared to the nsp4 site (0.891). This observation implied that the cleavage probabilities predicted
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purely based on protein sequence may show no strong correlation with cleavage efficiencies, indicating
that it is important to validate the results of in silico predictions in vitro.
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Figure 8. Cleavage of recombinant fusion protein substrates by SARS-CoV-2 3CLpro. His6-MBP-mEYFP
substrates containing TSAVLQ*SGFRKM (SARS-CoV-2 nsp4) or REGTRVQ*SVEQIRE (CTBP1) cleavage
site sequences were digested with SARS CoV-2 3CLpro. After SDS-PAGE, the gel was stained with
Coomassie dye. Uncleaved proteins and SARS-CoV-2 PR are shown by continuous and dashed
lines, respectively, while asterisks indicate cleavage products. Gel images are representatives of ≥ 2
parallel experiments.
The reaction mixtures were analyzed by matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS) and the molecular weights of cleavage fragments were determined
for the identification of cleavage positions. As was expected, the recombinant His6-MBP-mEYFP
substrate representing the nsp4 cleavage site sequence of the polyprotein (TSAVLQ*SGFRKM)
was cleaved within the incorporated sequence at the desired position (Figure 9a). After the cleavage of
recombinant CTBP1 protein, the analysis of cleavage fragments implied that the full-length protein is
cleaved at the predicted site (153GTRVQ*SVEQI162) (Figure 9b), and the recombinant His6-MBP-mEYFP
substrate containing the same cleavage site was also cleaved at the same predicted position (Figure 9c).
These results proved that the fluorescent substrates are suitable for fluorimetric assay.
2.7. Comparison of Cleavage Effic encies of SARS-CoV-2 and CTBP Cleavage Sites
After proving that the recombinant substrates are cleaved at the desired position (Figure 9),
we performed cleavage reactions using the His6-MBP-mEYFP substrates to demonstrate that the fusion
proteins are applicable for proteinase assays and to compare the cleavage efficiencies of SARS-CoV-2
and CTBP1 cleavage sites (Figure 10).
Cleavage reaction revealed that His6-MBP-TSAVLQ*SGFRKM-mEYFP substrate containing a
natural cleavage site of polyprotein is a better substrate of SARS-CoV-2 3CLpro as compared to the
CTBP cleavage site-containing substrate (Figure 10) (Table 2). This is in agreement with the results of
the gel-based assay which showed higher cleavage efficiency of His6-MBP-TSAVLQ*SGFRKM-mEYFP
substrate as compared to His6-MBP-REGTRVQ*SVEQIRE-mEYFP (Figure 8) but is in contrast with the
higher NetCorona score obtained for the latter cleavage site (Figure 3). Our results proved that the
designed substrates can be used for proteolytic assays, and show that the substrate is processed at the
incorporated CTBP1 only with low efficiency.
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Figure 9. Determination of cleavage sites by MALDI-TOF MS. In cleavage reactions His6-MBP-
TSAVLQ*SGFRKM-mEYFP (a), recombinant CTBP1 (b), and His6-MBP-REGTRVQ*SVEQIRE-mEYFP
proteins (c) were used as substrates. Molecular weights (Da) of SARS-CoV-2 3CLpro are labeled by
black, values for the full-length substrates are shown by dark blue color, while the proteolytic fragments
are colored by light blue and green, respectively. Cleavage site sequences are also shown, asterisks
indicate cleavage position.
Table 2. Kinetic p ram ters d termined for SARS-CoV-2 3CLpro using His6-MBP-TSAVLQ*SGFRKM-
mEYFP and His6-MBP-REGTRVQ*SVEQIRE-mEYFP substrates. Data were calculated based on the
results of two parallel experiments.
Cleavag Site KM (µM) kcat (s−1) kcat/KM (µM−1s−1)
TSAVLQ*SGFRKM 5.086 ± 2.046 1.349 ± 0.370 0.2652 ± 0.1291
REGTRVQ*SVEQIRE 0.860 ± 0.303 0.0033 ± 0.0004 0.0038 ± 0.0014
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His6-MBP-REGTRVQ*SVEQIRE-mEYFP (Figure 8) but is in contrast with the higher NetCorona 
score obtained for the latter cleavage site (Figure 3). Our results proved that the designed substrates 
can be used for proteolytic assays, and show that the substrate is processed at the incorporated 
CTBP1 only with low efficiency.  
The GTRVQ*SVEQI sequence motif is fully identical in the highly homologous CTBP1 and 
CTBP2 human proteins (Figure S2), therefore, CTBP2 is likely to be a target of SARS-CoV-2 3CL 
protease as well. In agreement with this, CTBP2 has been proved to be a proteolytic target of 
hCoV-NL63 3CLpro [21], and the highly similar cleavage site specificities imply that CTBP proteins 
may be potential targets of SARS-CoV and SARS-CoV-2 3CLpro enzymes, but their susceptibility 
for proteolytic cleavage needs to be investigated in the context of other cell types and/or species, as 
well. 
3. Discussion 
In this work, we aimed to test the application of such sequence-based algorithms for the 
prediction of SARS-CoV-2 3CLpro cleavage sites in different proteins which methods have already 
been applied in the case of SARS-CoV 3CLpro [26] or Zika and VEEV Group IV viral proteases 
[24,25]. 
Comparison of SARS-CoV and SARS-CoV-2 3CL proteases showed a high identity of protease 
sequences and substrate binding subsite compositions, which implied that the NetCorona v. 1.0 
webserver—that has been developed for the prediction of SARS-CoV 3CLpro cleavage sites 
[26]—may be potentially applicable to identify potential host targets of SARS-CoV-2 3CLpro. In 
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Figure 10. Kinetic analysis of SARS-CoV-2 3CLpro using recombinant fusion protein substrates.
Data obtained for His6-MBP-TSAVLQ*SGFRKM-mEYFP and His6-MBP-REGTRVQ*SVEQIRE-mEYFP
substrates are shown by full circles and squares, respectively. Averages of values obtained from two
parallel experiments are plotted, error bars represent SD. Kinetic parameters are shown in Table 2.
The GTRVQ*SVEQI sequence motif is fully identical in the highly homologous CTBP1 and CTBP2
human proteins (Figure S2), therefore, CTBP2 is likely to be a target of SARS-CoV-2 3CL protease as well.
In agreement with this, CTBP2 has been proved to be a proteolytic target of hCoV-NL63 3CLpro [21],
and the highly similar cleavage site specificities imply that CTBP proteins may be potential targets of
SARS-CoV and SARS-CoV-2 3CLpro enzymes, but their susceptibility for proteolytic cleavage needs to
be investigated in the context of other cell types and/or species, as well.
3. Discussion
In this work, we aimed to test the application of such sequence-based algorithms for the prediction
of SARS-CoV-2 3CLpro cl av ge sites in different proteins which methods have already been applied
i the case of SARS-CoV 3CL [26] or Zika and VEEV Group IV viral proteases [24,25].
Comparison of SARS-CoV and SARS-CoV-2 3CL proteases showed high identity of protease
sequences and su strate binding subsite compositions, which implied that the N tCorona v. 1.0
webserver—that has been developed for the prediction of SARS-CoV 3CLpro cleavage sites [26]—may
be potentially applicable to identify potential host targets of SARS-CoV-2 3CLpro. In addition,
identifica io of SSHHPS using BLAST analysis may be applied to identify putativ target equenc
of PLpro, however, pr diction potenti l was not ested in this context.
The most probable candidate host substrates were considered to contain SSHHPS and/or a potential
cleavage site with a high NetCorona score, and of the candidate targets, we selected CTBP1 and PTK6
proteins and investigated their susceptibility for proteoly is in vitr . Additionally, IR K1, which has
already been predicted pr viously to contain a potential cleavage site of SARS-CoV 3CLp o [26],
was also studied, and we proved that it is a substrate of SARS-CoV-2 3CLpro. Plasma r tein
PLMN—containing predicted cleavage site—was not digested by SARS-CoV-2 3CLpro, possibly due
to inaccessibility of the cleavage site in the structure.
A His6-MBP-TSAVLQ*SGFRKM-mEYFP recombinant substrate—containing a natural cleavage
site of SARS-CoV-2 polyprotein—was designed and used as a positive control in cleavage reactions.
This substrate system has already been applied previously to study proteases of HIV-1, tobacco etch
virus [33–35], yeast Ty1 retrotransposon [36], and Venezuelan equine encephalitis virus (VEEV) [37],
and the protease of human paternally expressed gene 10 (PEG10) protein [38]. The successful adaptation
of this recombinant substrate system enables enzymatic characterization of SARS-CoV-2 3CLpro and
screening of inhibitors using a microcentrifuge tube- [33,36] or a microtiter plate-based protease
assay [34,37] in the future. Furthermore, a wide variety of sequences can be potentially inserted into
recombinant substrates, making specificity studies and target site identifications possible.
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CTBP1 is a transcriptional co-repressor protein that is involved in the regulation of the expression of
genes controlling development, oncogenesis, and apoptosis [39]. CTBP1 and -2 were found previously
to influence viral replication, and enhanced replication of adenovirus E1A was observed upon CTBP
knockdown [40]. PTK6 is also referred to as breast tumor kinase, and is an intracellular non-receptor
tyrosine kinase, while PLMN is the zymogen form of plasmin being responsible for digestion of fibrin
clot (fibrinolysis). Here we identified both proteins as candidate targets of SARS-CoV-2 3CLpro, but we
did not observe their processing in spite of the presence of a putative cleavage site (predicted by the
NetCorona webserver).
The sets of experimentally determined cleavage sites—e.g., obtained from in vitro proteomic
analysis [21]—are expected to aid the improvement of prediction algorithms’ reliability, while our
results also represented some limitations of the applied in silico methods and highlighted the necessity
of structural analysis and determination of cleavage site accessibilities, otherwise, candidate targets
can be identified only with lower accuracy.
In summary, we have successfully adapted the SSHHPS analysis for the identification of potential
coronavirus cleavage sites, and “repurposed” the NetCorona 1.0 webserver for the prediction of
candidate human target proteins of SARS-CoV-2 3CLpro. We demonstrated that the NetCorona
1.0 webserver developed primarily for the 3CLpro of SARS-CoV is applicable efficiently for that of
SARS-CoV-2, as well. The NetCorona webserver can be applied for the prediction of 3CLpro cleavage
sites, while our results implied that SSHHPS analysis may be used to identify substrates of PLpro,
as well, however, we have not tested PLpro in vitro. The prediction algorithms were tested only for
human proteins, but they can be potentially adapted for the identification of host targets in other
species as well.
Our results highlighted a limitation of sequence-based cleavage site predictions and showed
that the structural context of cleavage sites also need to be considered because the regions with the
lower solvent-accessible surface may be less susceptible for proteolysis, even a high NetCorona score.
We identified CTBP1 protein as a host substrate of SARS-CoV-2 3CLpro, and the existence of the
predicted cleavage site was successfully proved experimentally both in the case of the recombinant
CTBP1 and the His6-MBP-REGTRVQ*SVEQIRE-mEYFP substrate. Nonetheless, it is important to
note that the CTBP cleavage site was processed with remarkably lower efficiency. Based on homology
we assume that human CTBP2 is also a host substrate of the protease, but future studies need to
reveal how processing of the CTBP proteins play role in the viral life-cycle. Identification of additional
molecular targets of SARS-CoV and SARS-CoV-2 3CL proteases may help better understanding of
viral replication, pathogenesis, and the coronavirus-induced phenotypes.
4. Materials and Methods
4.1. In Silico Analyses
4.1.1. BLAST Analysis
Autoproteolytic cleavage site sequences of SARS-CoV-2 3CLpro were obtained from the
literature [18]. BLAST analysis was performed to identify SSHHPS in human proteins, using the
cleavage site sequences as input. Human-specific sequence search was run in BLASTP-as part of the
BLAST+ 2.10.0—using the “blastp-short” option with PAM30 scoring matrix optimized for query
sequences shorter than 30 residues [41,42]. The 10 residue-long query sequences (P5–P5’ residues) were
aligned against the nr BLAST database (all non-redundant databases including GenBank translations,
PDB, SwissProt, PIR, and PRF entries, excluding environmental samples from WGS projects) consisting
of a total of 281,252,422 sequences. In order to include partially aligned hits of the catalytic residues,
and those of similar physicochemical characteristics the following parameter values were set: window
length, 15; cutoff value, 25,500; threshold score, 5.
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4.1.2. NetCorona Prediction
NetCorona v. 1.0 webserver (available at http://www.cbs.dtu.dk/services/NetCorona/) was applied
to predict the presence of SARS-CoV-2 3CLpro cleavage sites [26], using sequences of full-length
proteins as input. The default threshold of the NetCorona algorithm is 0.5. The higher prediction
score indicates higher cleavage probability, the most probable cleavage sites were identified with > 0.8
prediction score.
4.1.3. Structures
Coordinate files were downloaded from Protein Data Bank [43]. We used X-ray crystal structures
of SARS-CoV-2 3CLpro (6LU7.pdb) [13], CTBP1 (4U6Q.pdb) [44], PLMN (1DDJ.pdb) [45], and ACHE
proteins (1B41.pdb) [46], and a NMR solution structure of PTK6 (1RJA.pdb) [47]. The homology model
of IRAK1 was downloaded from SWISS-MODEL Repository [48], the model has been prepared based
on X-ray crystal structure of the protein (6BFN.pdb) [49].
The per-residue solvent accessible surface areas (SASA) were computed based on the coordinate
files using Lee and Richard’s algorithm with default probe-radius (1.4 Å) at a resolution of 200 slices per
atom by FreeSASA tool [50]. Structural figures were prepared by using the PyMol Molecular Graphics
System (V. 1.3 Schrödinger, LLC). Sequence logos were prepared by the WebLogo 3 webserver [51].
4.2. In Vitro Analyses
4.2.1. Materials
All materials were obtained from Sigma-Aldrich, otherwise, it is indicated. The purified
recombinant human CTBP1 (ab93729), PTK6 (ab60888), and IRAK1 tagged with an N-terminal
glutathione-S-transferase (ab268679) were ordered from Abcam, PLMN from Chromogenix, while BSA
(A7030) from Sigma-Aldrich (St. louis, MO, USA). Lyophilized BSA and PLMN were dissolved in
distilled water (1 mg/mL stock).
4.2.2. Expression and Purification of SARS-CoV-2 3CLpro
A pET11a plasmid bearing the coding sequence of SARS-CoV-2 3CLpro (GenBank: MT291835.2)
fused to an N-terminal hexahistidine tag (His6) was obtained using the gene synthesis service
of GenScript.
The pET11 bacterial expression plasmid coding for His6-SARS-CoV-2 3CLpro was transformed
into BL21(DE3) E. coli cells. For protein expression, transformant cells were cultured at 37 ◦C in
Luria-Bertani (LB) medium supplemented with ampicillin (100 µg/mL final concentration). Expression
of the protease was induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) in 1 mM
final concentration, followed by shaking the suspensions at 37 ◦C for 3 h. After incubation, cells were
collected by centrifugation at 4 ◦C for 20 min at 5000× g (Sorvall Lynx 4000, Thermo Fisher Scientific,
Waltham, MA, USA). The pelleted cells were lysed in buffer A (20 mM Tris, 150 mM NaCl, 10 mM
imidazole, pH 7.5) followed by sonication (Branson Sonifier 450) and centrifugation at 4 ◦C for 20 min at
10,000× g. His6-SARS-CoV-2 3CLpro was purified from the supernatant by a His-Trap Ni-chelate affinity
chromatography column (GE Healthcare) using the Äkta Prime instrument (Amersham Pharmacia
Biotech, Little Chalfont, UK). The buffer of the eluate was changed to buffer B (20 mM Tris, 1 mM DTT,
pH 8.0) by ultrafiltration using Amicon Ultra centrifugal filters (10K, Merck Millipore, Burlington,
MA, USA), followed by removal of His6-tag by digesting His6-SARS-CoV-2 3CLpro using Factor
Xa (BCXA-1060, Haematologic Technologies, Essex Junction, VT, USA). Purification of the untagged
protease was performed by ion-exchange chromatography using HiTrap Q FF column (GE Healthcare,
Chicago, IL, USA). Finally, the fractions were dialyzed against buffer C (20 mM Tris, 150 mM NaCl,
1 mM EDTA, 1 mM DTT, pH 7.8), and stored at −20 ◦C. The purity of the fractions was determined
by SDS-PAGE.
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4.2.3. Vector Construction for the Expression of a His6-MBP-mEYFP Substrates
The coding sequences of cleavage sites were cloned into a pDest-His6-MBP-mEYFP bacterial
expression plasmid, based on the method described previously [33,34], the applied oligonucleotide
primers and the cleavage site sequences are shown in Table 3. The success of cloning was confirmed
by a DNA sequencing service (Eurofins Genomics Germany GmbH; Ebersberg, Germany), followed
by a transformation of the verified pDest-His6-MBP-mEYFP expression constructs into BL21(DE3)
E. coli cells.
Table 3. Oligonucleotide primers used for cloning. pDest-His6-MBP-mEYFP expression vectors
were prepared by ligating the following complementary oligonucleotide primer pairs—coding for the
cleavage site sequences-into the plasmid. CTBP1 (151–164) sequence is fully identical in CTBP1 and
CTBP2 proteins. FW: forward; RV: reverse.
Cleavage Site Sequence Oligonucleotide Primer Sequence
SARS-CoV-2
nsp4
TSAVLQ*
SGFRKM
FW: 5’-TAAAACCTCTGCGGTGCTGCAGTCTGGCTTTCGTAAAATGG-3’
RV: 5’-CTAGCCATTTTACGAAAGCCAGACTGCAGCACCGCAGAGGTTTTAAT-3’
CTBP1/2
(151–164)
REGTRV*
SVEQIRE
FW: 5’-TAAACGTGAAGGCACCCGTGTGCAGTCTGTGGAACAGATCCGTGAAG-3’
RV: 5’-CTAGCTTCACGGATCTGTTCCACAGACTGCACACGGGTGCCTTCACGTTTAAT-3’
4.2.4. Expression and Purification of the His6-MBP-mEYFP Substrates
The His6-MBP-mEYFP protein substrates (Table 3) were expressed in BL21(DE3) E. coli cells based
on the protocol described previously [33,34] with slight modifications. After expression at 37 ◦C,
cells were collected by centrifugation, the pellet was suspended in lysis buffer (20 mM Tris HCl, 100 mM
NaCl, 5 mM imidazole, pH 7.8), followed by sonication and centrifugation. The recombinant proteins
were purified from the cleared cell lysates using Ni-NTA magnetic agarose beads (Cube Biotech,
Germany) [33–35]. After purification, the elution buffer (100 mM EDTA, 0.05% Tween 20, pH 8.0)
was exchanged for distilled water, and the total protein concentration was determined by measuring
absorbance at 280 nm using NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA). Sample
purity was determined by SDS-PAGE, using 14% polyacrylamide gel. The purified fusion proteins
were then used in cleavage reactions as substrates of SARS-CoV-2 3CLpro.
4.2.5. Cleavage Reactions by SARS-CoV-2 3CLpro
For cleavage reaction, the recombinant proteins were incubated with purified SARS-CoV-2 3CLpro
in reaction buffer (20 mM Tris, 100 mM NaCl, pH 7.8) at 37 ◦C for at least 1 h. To analyze cleavage
reactions by SDS-PAGE, the polyacrylamide gels were stained by Coomassie dye. In some cases,
the denaturing SDS-PAGE was followed by in-gel renaturation of His6-MBP-mEYFP substrates by
rinsing the gel in distilled water. The uncleaved substrate and cleavage products were visualized in
the unstained gel based on their fluorescence under UV light using AlphaImager gel documentation
system (ProteinSimple) [33–35], then the gel was stained by Coomassie dye as well.
4.2.6. Cleavage Site Identification by MALDI-TOF MS
For the identification of cleavage sites, the reaction mixtures were concentrated and desalted
by using C4 ZipTip pipette tips (ZTC04S096, Sigma-Aldrich, St. Louis, MO, USA), based on the
instructions of the manufacturer. 2,5-dihydroxybenzoic acid (DHB) (100 mg/mL) was applied as matrix
dissolved in 50% aqueous acetonitrile with 0.1% TFA content. 0.5 µL matrix and 1 µL sample was
deposited and mixed on the plate and was allowed to dry.
The mass spectrometric measurements were performed with a Bruker Autoflex Speed MALDI-TOF
mass spectrometer. The linear mode was used for all samples, where the ion source voltage 1 and ion
source voltage 2 were 19.5 kV, 18.3 kV, respectively. The applied laser was a solid phase laser (355 nm,
≥100 µJ/pulse) utilized at 200 Hz and 10,000 shots were summed. The results were evaluated by the
flexAnalysis software (Bruker, Billerica, MA, USA).
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4.2.7. Proteinase Assay with His6-MBP-mEYFP Substrates
The magnetic bead-based assay was performed based on the method described previously [33–36]
with slight modifications. Cleavage reactions were performed in reaction buffer (20 mM Tris, 100 mM
NaCl, pH 7.8) by incubating samples at 37 ◦C for 10 min. For the measurements with His6-MBP-
TSAVLQ*SGFRKM-mEYFP and His6-MBP-REGTRVQ*SVEQIRE-mEYFP substrates the enzyme was
applied in 0.074 µM and 0.74 µM final concentration, respectively. Due to the lack of any selective
tight-binding inhibitors, the determination of the active site concentration was not possible, and the
activity of SARS-CoV-2 3CLpro was regarded as 100%. Fluorimetric measurements were performed
using a Biotek Synergy H1 device at 510 nm excitation and 540 nm emission wavelengths.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/24/
9523/s1.
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3CLpro 3-chymotrypsin-like protease (main protease)
COVID-19 coronavirus disease-19
CTBP1 C-terminal-binding protein 1
CTBP2 C-terminal-binding protein 2
MBP Maltose-binding protein
mEYFP Monomeric enhanced yellow fluorescent protein
PLpro Papain-like protease
PR Protease
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
SSHHPS Short stretches of homologous host-pathogen protein sequences
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34. Bozóki, B.; Mótyán, J.A.; Miczi, M.; Gazda, L.D.; Tőzsér, J. Use of Recombinant Fusion Proteins in a Fluorescent
Protease Assay Platform and Their In-gel Renaturation. J. Vis. Exp. 2019, 16, e58824. [CrossRef] [PubMed]
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